Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P140017/S035

Melody Transcatheter Pulmonary Valve System, which includes the Melody Transcatheter Pulmonary Valve (Melody TPV) and th

Medtronic, Inc. · Decision date Jun 9, 2026

FDA DECISIONP140017/S035

What did the FDA approve?

FDA records P140017/S035 as a supplement to PMA P140017, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Jun 9, 2026.

FDA approval order statement

Approval for secondary packaging changes, including a new shipping temperature indicator, and minor labeling changes.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Jun 9, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P140017/S035
Regulatory pathway
PMA supplement
Product code
NPV
Decision code
APPR
Decision date
Jun 9, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Pulmonary valve prosthesis percutaneously delivered.

Product code
NPV
FDA device class
f

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P140017/S031 · Related supplement

    Melody Transcatheter Pumonary Valve System

  2. P140017/S032 · Related supplement

    Melody Transcatheter Pulmonary Valve

  3. P140017/S033 · Related supplement

    Melody Transcatheter Pulmonary Valve

  4. P140017/S035 received

    Application receipt date recorded by FDA.

  5. P140017/S034 · Related supplement

    Melody Transcatheter Pulmonary Valve

  6. P140017/S036 · Related supplement

    Melody Transcatheter Pulmonary Valve

  7. P140017/S035 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P140017. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P140017

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA supplementAug 21, 2025FDA
Medtronic, Inc.PMA supplementOct 23, 2025FDA
Medtronic, Inc.PMA supplementFeb 12, 2026FDA
Medtronic, Inc.PMA supplementApr 9, 2026FDA
Medtronic, Inc.PMA supplementJun 1, 2026FDA

Explore the linked device profile

Other records with product code NPV

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
8200 Coral Sea St. NE Mvs83, Mounds View, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records